 | |||||
| in | |||||
| WEB | |||||
| Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19 The study demonstrated that patients in the 5-day remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 ...
| |||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
ShareThis
No comments:
Post a Comment